There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Endologix Inc (ELGX), Aerie Pharma (AERI) and Evofem Biosciences Inc (EVFM) with bullish sentiments.
Endologix Inc (ELGX)
BTIG analyst Sean Lavin reiterated a Buy rating on Endologix Inc yesterday and set a price target of $4. The company’s shares opened today at $0.54, close to its 52-week low of $0.52.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 10.8% and a 60.4% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Currently, the analyst consensus on Endologix Inc is a Moderate Buy with an average price target of $4.
See today’s analyst top recommended stocks >>
Aerie Pharma (AERI)
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aerie Pharma today and set a price target of $85. The company’s shares opened today at $39.50.
Piros observed:
“: We reiterate our Overweight rating and are lowering our 12-month price target to $85/share from $86/share on AERI. Aerie Pharmaceuticals reported earnings and hosted a conference call to discuss financial and corporate updates for 4Q18/2018. The quarter produced strong Rhopressa sales of $14.5 million. Our focus in 2019 will be on a potential Rocklatan approval, company guidance for revenue projections, and the international expansion of Aerie’s glaucoma drugs to further penetrate the market potential.”
According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.5% and a 42.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $77.40, implying a 95.9% upside from current levels. In a report issued on February 12, Canaccord Genuity also reiterated a Buy rating on the stock with a $86 price target.
Evofem Biosciences Inc (EVFM)
In a report released today, Matthew Lillis from Cantor Fitzgerald reiterated a Buy rating on Evofem Biosciences Inc, with a price target of $9. The company’s shares opened today at $3.80.
Lillis observed:
“: We reiterate our Overweight rating and $9 PT. We believe Amphora could become an important alternative with which to prevent pregnancy, particularly for women not using hormonal or device-related methods. AMP002 pivotal trial support that Amphora is safe and effective, in our view, while the hormone-free composition, as-needed dosing, and 98.7% perfect-use efficacy rate, approaching that of oral contraceptives, add compelling arguments relative to other options. As EVFM moves toward a longer-term financial strategy to fund the precommercial activities and launch of Amphora, if approved, we think management may consider potential sources of non-dilutive capital that may benefit shareholders.”
According to TipRanks.com, Lillis is a 2-star analyst with an average return of 4.0% and a 66.7% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Supernus Pharmaceuticals, and Amag Pharmaceuticals.
Evofem Biosciences Inc has an analyst consensus of Strong Buy, with a price target consensus of $10.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
